Cargando…

Energy Balance in Hypothalamic Obesity in Response to Treatment with a Once-Weekly GLP-1 Receptor Agonist

BACKGROUND/OBJECTIVES: Hypothalamic obesity (HO) frequently occurs following suprasellar tumors from a combination of decreased energy expenditure and increased energy intake. Glucagon-like peptide-1 receptor agonist (GLP1RA) therapy is associated with increased satiety and energy expenditure. We hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shoemaker, Ashley H., Silver, Heidi J., Buchowski, Maciej, Slaughter, James C., Yanovski, Jack A., Elfers, Clinton, Roth, Christian L., Abuzzahab, M. Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881399/ https://www.ncbi.nlm.nih.gov/pubmed/34975146 http://dx.doi.org/10.1038/s41366-021-01043-6

Ejemplares similares

A phase 3 randomized clinical trial using a once‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesity
por: Roth, Christian L., et al.
Publicado: (2020)

RF04 | PSUN295 Evolution of Monomeric Multi-Agonists of GLP-1 and NPY Receptors
por: Chichura, Kylie, et al.
Publicado: (2022)

An overview of the once‐weekly GLP‐1 receptor agonists from the pharmacist’s perspective
por: Patel, Dhiren
Publicado: (2020)

Activation of nuclear factor kappa B pathway and reduction of hypothalamic oxytocin following hypothalamic lesions
por: Roth, Christian L., et al.
Publicado: (2016)

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
por: Trujillo, Jennifer
Publicado: (2020)

Effects of Methylphenidate on Weight Gain and Food Intake in Hypothalamic Obesity
por: Elfers, Clinton Thomas, et al.
Publicado: (2011)

Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Goldman, Jennifer D.
Publicado: (2020)

Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes
por: Di Dalmazi, Giulia, et al.
Publicado: (2022)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

Glycaemic and non‐glycaemic efficacy of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Patel, Dhiren
Publicado: (2020)

Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity
por: Roth, Christian L., et al.
Publicado: (2015)

Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices
por: Zhou, Anna Y., et al.
Publicado: (2018)

Managing the multifaceted nature of type 2 diabetes using once‐weekly injectable GLP‐1 receptor agonist therapy
por: Bzowyckyj, Andrew
Publicado: (2020)

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
por: Kaneko, Shizuka
Publicado: (2022)

FRI082 Impact Of Setmelanotide On Metabolic Parameters And Vital Signs In Patients With Hypothalamic Obesity
por: Jennifer Abuzzahab, M, et al.
Publicado: (2023)

SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents
por: Cornell, Susan
Publicado: (2020)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial
por: Roth, Christian L, et al.
Publicado: (2023)

Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis
por: Milliken, Brandon T., et al.
Publicado: (2021)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Kayaniyil, Sheena, et al.
Publicado: (2016)

A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
por: Webb, Neil, et al.
Publicado: (2018)

A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss
por: Chichura, Kylie S., et al.
Publicado: (2023)

FRI065 Trial Design Of A Double-blind, Randomized, Placebo-controlled, Phase 3 Study Of Setmelanotide In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

FRI064 The Role Of GLP-1 Receptor Agonists In The Treatment Of Pituitary And Hypothalamic Tumor Induced Obesity
por: Botero Suarez, Carlos S, et al.
Publicado: (2023)

The renoprotective effect of once‐weekly GLP‐1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type 2 diabetes and moderate to severe chronic kidney disease (JDDM67)
por: Tsuchida, Ken‐ichi, et al.
Publicado: (2022)

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin
por: Witkowski, Michal, et al.
Publicado: (2018)

Semaglutide, a Once-Weekly Human GLP-1 Analog, Does Not Reduce the Bioavailability of the Combined Oral Contraceptive, Ethinylestradiol/Levonorgestrel
por: Kapitza, Christoph, et al.
Publicado: (2015)

Glucose in the hypothalamic paraventricular nucleus regulates GLP-1 release
por: Ma, Yue, et al.
Publicado: (2020)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Assessment of disturbed glucose metabolism and surrogate measures of insulin sensitivity in obese children and adolescents
por: Roth, Christian L, et al.
Publicado: (2017)

Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists
por: Handelsman, Yehuda, et al.
Publicado: (2018)

Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance
por: Cacciatori, Vittorio, et al.
Publicado: (2017)

Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance
por: Hardonova, Miroslava, et al.
Publicado: (2023)

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
por: Nauck, Michael A., et al.
Publicado: (2015)

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
por: Lingvay, Ildiko, et al.
Publicado: (2021)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gtmq51945nd0770brvidvl38t8